TY - JOUR
T1 - Randomized clinical trial of latanoprost and unoprostone in patients with elevated intraocular pressure
AU - Jampel, Henry D.
AU - Bacharach, Jason
AU - Sheu, Wang Pui
AU - Wohl, Lisa G.
AU - Solish, Alfred M.
AU - Christie, William
N1 - Funding Information:
This study was supported by Pharmacia Corporation, Peapack, New Jersey. Ms. Sheu is an employee of Pharmacia Corporation. Medications used in the study were provided by Pharmacia Corporation.
Copyright:
Copyright 2008 Elsevier B.V., All rights reserved.
PY - 2002/12/1
Y1 - 2002/12/1
N2 - PURPOSE: To compare the intraocular pressure (IOP)-lowering effect and safety of latanoprost 0.005% once daily with that of unoprostone 0.15% twice daily for patients with primary open-angle glaucoma or ocular hypertension. DESIGN: Randomized clinical trial. METHODS: In a prospective, 8-week, investigator-masked, parallel-group study conducted at numerous centers in the United States, 165 previously treated patients with IOP ≥ 25 mm Hg in one or both eyes after washout were randomly assigned to receive either latanoprost 0.005% once daily in the evening or unoprostone 0.15% twice daily. Observations procedures were Goldmann applanation tonometry, best-corrected visual acuity, slit lamp biomicroscopy, and ophthalmoscopy. The main outcome measure was change in the mean of the IOPs measured at 8:00 AM, 12 noon, and 4:00 PM between baseline (before treatment) and after 8 weeks of treatment. RESULTS: The change in the mean ± SD of the IOPs measured at 8:00 AM, 12 noon, and 4:00 PM was -7.2 ± 3.2 mm Hg (28%) for latanoprost (25.3 ± 2.8 mm Hg at baseline to 18.2 ± 2.8 mm Hg at 8 weeks) and -3.9 ± 2.6 mm Hg (15%) for unoprostone (25.5 ± 3.3 mm Hg at baseline to 21.6 ± 4.0 mm Hg; P ≤ .001. No serious adverse event related to either medication was reported. CONCLUSIONS: Over an 8-week period, latanoprost 0.005% once daily lowered IOP more than unoprostone 0.15% twice daily in patients with elevated IOP. Both agents were safe and well tolerated.
AB - PURPOSE: To compare the intraocular pressure (IOP)-lowering effect and safety of latanoprost 0.005% once daily with that of unoprostone 0.15% twice daily for patients with primary open-angle glaucoma or ocular hypertension. DESIGN: Randomized clinical trial. METHODS: In a prospective, 8-week, investigator-masked, parallel-group study conducted at numerous centers in the United States, 165 previously treated patients with IOP ≥ 25 mm Hg in one or both eyes after washout were randomly assigned to receive either latanoprost 0.005% once daily in the evening or unoprostone 0.15% twice daily. Observations procedures were Goldmann applanation tonometry, best-corrected visual acuity, slit lamp biomicroscopy, and ophthalmoscopy. The main outcome measure was change in the mean of the IOPs measured at 8:00 AM, 12 noon, and 4:00 PM between baseline (before treatment) and after 8 weeks of treatment. RESULTS: The change in the mean ± SD of the IOPs measured at 8:00 AM, 12 noon, and 4:00 PM was -7.2 ± 3.2 mm Hg (28%) for latanoprost (25.3 ± 2.8 mm Hg at baseline to 18.2 ± 2.8 mm Hg at 8 weeks) and -3.9 ± 2.6 mm Hg (15%) for unoprostone (25.5 ± 3.3 mm Hg at baseline to 21.6 ± 4.0 mm Hg; P ≤ .001. No serious adverse event related to either medication was reported. CONCLUSIONS: Over an 8-week period, latanoprost 0.005% once daily lowered IOP more than unoprostone 0.15% twice daily in patients with elevated IOP. Both agents were safe and well tolerated.
UR - http://www.scopus.com/inward/record.url?scp=0036895931&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0036895931&partnerID=8YFLogxK
U2 - 10.1016/S0002-9394(02)01820-2
DO - 10.1016/S0002-9394(02)01820-2
M3 - Article
C2 - 12470755
AN - SCOPUS:0036895931
SN - 0002-9394
VL - 134
SP - 863
EP - 871
JO - American journal of ophthalmology
JF - American journal of ophthalmology
IS - 6
ER -